#BEGIN_DRUGCARD DB04237

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C7H17NO3

# Chemical_IUPAC_Name:
3-amino-3-(2-hydroxyethyl)pentane-1,5-diol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Tris(Hydroxyethyl)Aminomethane

# HET_ID:
TAM

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C7H17NO3/c8-7(1-4-9,2-5-10)3-6-11/h9-11H,1-6,8H2

# InChI_Key:
InChIKey=GKODZWOPPOTFGA-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4237

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
163.2148

# Molecular_Weight_Mono:
163.120843415

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1Q4N

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.6

# Predicted_LogS:
0.25

# Predicted_Water_Solubility:
2.91e+02 g/l

# Primary_Accession_No:
DB04237

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
448009

# PubChem_Substance_ID:
46506740

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT03004

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC(CCO)(CCO)CCO

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:07 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Secreted protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
AMY1A

# Drug_Target_1_GenBank_ID_Gene:
M18786

# Drug_Target_1_GenBank_ID_Protein:
178585

# Drug_Target_1_GeneCard_ID:
AMY1A

# Drug_Target_1_Gene_Name:
AMY1A

# Drug_Target_1_Gene_Sequence:
>1536 bp
ATGAAGCTCTTTTGGTTGCTTTTCACCATTGGGTTCTGCTGGGCTCAGTATTCCTCAAAT
ACACAACAAGGACGAACATCTATTGTTCATCTGTTTGAATGGCGATGGGTTGATATTGCT
CTTGAATGTGAGCGATATTTAGCTCCCAAGGGATTTGGAGGGGTTCAGGTCTCTCCACCA
AATGAAAATGTTGCCATTCACAACCCTTTCAGACCTTGGTGGGAAAGATACCAACCAGTT
AGCTATAAATTATGCACAAGATCTGGAAATGAAGATGAATTTAGAAACATGGTGACTAGA
TGCAACAATGTTGGGGTTCGTATTTATGTGGATGCTGTAATTAATCATATGTGTGGTAAT
GCTGTGAGTGCAGGAACAAGCAGTACCTGTGGAAGTTACTTCAACCCTGGAAGTAGGGAC
TTTCCAGCAGTCCCATATTCTGGATGGGATTTTAATGATGGTAAATGTAAAACTGGAAGT
GGAGATATCGAGAACTATAATGATGCTACTCAGGTCAGAGATTGTCGTCTGTCTGGTCTT
CTCGATCTTGCACTGGGGAAGGATTATGTGCGTTCTAAGATTGCCGAATATATGAACCAT
CTCATTGACATTGGTGTTGCAGGGTTCAGAATTGATGCTTCCAAGCACATGTGGCCTGGA
GACATAAAGGCAATTTTGGACAAACTGCATAATCTAAACAGTAACTGGTTCCCGGAAGGT
AGTAAACCTTTCATTTACCAGGAGGTAATTGATCTGGGTGGTGAGCCAATTAAAAGCAGT
GACTACTTTGGTAATGGCCGGGTGACAGAATTCAAGTATGGTGCAAAACTCGGCACAGTT
ATTCGCAAGTGGAATGGAGAGAAGATGTCTTACTTAAAGAACTGGGGAGAAGGTTGGGGT
TTCATGCCTTCTGACAGAGCGCTTGTCTTTGTGGATAACCATGACAATCAACGAGGACAT
GGCGCTGGAGGAGCCTCTATACTTACCTTCTGGGATGCTAGGCTGTACAAAATGGCAGTT
GGATTTATGCTTGCTCATCCTTATGGATTTACACGAGTAATGTCAAGCTACCGTTGGCCA
AGATATTTTGAAAATGGAAANGATGTTAATGATTGGGTTGGGCCACCAAATGATAATGGA
GTAACTAAAGAAGTTACTATTAATCCAGACACTACTTGTGGCAATGACTGGGTCTGTGAA
CATCGATGGCGCCAAATAAGGAACATGGTTAATTTCCGCAATGTAGTGGATGGCCAGCCT
TTTACAAACTGGTATGATAATGGGAGCAACCAAGTGGCTTTTGGGAGAGGAAACAGAGGA
TTCATTGTTTTCAACAATGATGACTGGACATTTTCTTTAACTTTGCAAACTGGTCTTCCT
GCTGGCACATACTGTGATGTCATTTCTGGAGATAAAATTAATGGCAACTGCACAGGCATT
AAAATCTACGTTTCTGATGATGGCAAAGCTCATTTTTCTATTAGTAACTCTGCTGAAGAT
CCATTTATTGCAATTCATGCTGAATCTAAATTGTAA

# Drug_Target_1_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_1_General_References:
12527308	Ramasubbu N, Ragunath C, Mishra PJ: Probing the role of a mobile loop in substrate binding and enzyme activity of human salivary amylase. J Mol Biol. 2003 Jan 31;325(5):1061-76.
1710976	Bank RA, Hettema EH, Arwert F, Amerongen AV, Pronk JC: Electrophoretic characterization of posttranslational modifications of human parotid salivary alpha-amylase. Electrophoresis. 1991 Jan;12(1):74-9.
2423416	Nishide T, Nakamura Y, Emi M, Yamamoto T, Ogawa M, Mori T, Matsubara K: Primary structure of human salivary alpha-amylase gene. Gene. 1986;41(2-3):299-304.
2452973	Gumucio DL, Wiebauer K, Caldwell RM, Samuelson LC, Meisler MH: Concerted evolution of human amylase genes. Mol Cell Biol. 1988 Mar;8(3):1197-205.
6610603	Nishide T, Emi M, Nakamura Y, Matsubara K: Corrected sequences of cDNAs for human salivary and pancreatic alpha-amylases [corrected] Gene. 1984 May;28(2):263-70.

# Drug_Target_1_HGNC_ID:
HGNC:474

# Drug_Target_1_HPRD_ID:
00096

# Drug_Target_1_ID:
3030

# Drug_Target_1_Locus:
1p21

# Drug_Target_1_Molecular_Weight:
57768

# Drug_Target_1_Name:
Salivary alpha-amylase

# Drug_Target_1_Number_of_Residues:
511

# Drug_Target_1_PDB_ID:
1MFV

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00128	Alpha-amylase
PF02806	Alpha-amylase_C

# Drug_Target_1_Protein_Sequence:
>Salivary alpha-amylase precursor
MKLFWLLFTIGFCWAQYSSNTQQGRTSIVHLFEWRWVDIALECERYLAPKGFGGVQVSPP
NENVAIHNPFRPWWERYQPVSYKLCTRSGNEDEFRNMVTRCNNVGVRIYVDAVINHMCGN
AVSAGTSSTCGSYFNPGSRDFPAVPYSGWDFNDGKCKTGSGDIENYNDATQVRDCRLSGL
LDLALGKDYVRSKIAEYMNHLIDIGVAGFRIDASKHMWPGDIKAILDKLHNLNSNWFPEG
SKPFIYQEVIDLGGEPIKSSDYFGNGRVTEFKYGAKLGTVIRKWNGEKMSYLKNWGEGWG
FMPSDRALVFVDNHDNQRGHGAGGASILTFWDARLYKMAVGFMLAHPYGFTRVMSSYRWP
RYFENGKDVNDWVGPPNDNGVTKEVTINPDTTCGNDWVCEHRWRQIRNMVNFRNVVDGQP
FTNWYDNGSNQVAFGRGNRGFIVFNNDDWTFSLTLQTGLPAGTYCDVISGDKINGNCTGI
KIYVSDDGKAHFSISNSAEDPFIAIHAESKL

# Drug_Target_1_Reaction:
Endohydrolysis of 1,4-alpha-D-glucosidic linkages in polysaccharides containing three or more 1,4-alpha-linked D-glucose units ALL_REAC (other) R02108 R06209(G)

# Drug_Target_1_Signals:
1-15

# Drug_Target_1_Specific_Function:
Endohydrolysis of 1,4-alpha-D-glucosidic linkages in oligosaccharides and polysaccharides

# Drug_Target_1_SwissProt_ID:
P04745

# Drug_Target_1_SwissProt_Name:
AMY1_HUMAN

# Drug_Target_1_Synonyms:
1,4-alpha-D-glucan glucanohydrolase
EC 3.2.1.1
Salivary alpha-amylase precursor

# Drug_Target_1_Theoretical_pI:
6.92

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
AF003948

# Drug_Target_2_GenBank_ID_Protein:
2935033

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
clcA

# Drug_Target_2_Gene_Sequence:
>774 bp
ATGGCCAATACACGCGTGATCGAGTTGTTCGACGAATTCACCGATCTCATCCGTGATTTC
ATCGTCCGTCACGAGATCACCACACCGGAGTACGAAACGATCATGCAATACATGATCAGC
GTCGGCGAGGCCGGCGAGTGGCCGCTGTGGCTCGACGCGTTCTTCGAAACCACCGTCGAC
TCCGTGAGCTACGGCAAGGGAAACTGGACCTCCAGTGCGATCCAAGGACCGTTCTTCAAA
GAAGGTGCCCCGCTGCTGACCGGCAAACCGGCCACCCTGCCGATGCGGGCAGACGAGCCT
GGCGACCGGATGCGGTTCACCGGGAGCGTGCGCGACACGTCGGGAACTCCGATCACCGGC
GCGGTCATCGATGTGTGGCACTCCACCAACGACGGCAACTACAGCTTTTTCTCCCCCGCT
CTGCCCGACCAGTACCTGCTGCGCGGCAGGGTCGTCCCCGCCGAAGACGGCAGCATCGAG
TTCCACAGCATCCGACCGGTGCCCTACGAAATCCCGAAAGCTGGCCCCACGGGCCAGCTC
ATGAACTCATACCTCGGCCGGCACTCCTGGCGCCCCGCACACATCCACATCCGCATCACC
GCCGACGGGTACCGGCCACTGATCACCCAGCTCTACTTCGAGGGCGACCCGTACCTGGAC
AGCGACTCCTGCTCGGCAGTCAAGAGCGAACTGGTTCTGCCGGTCAACAAGATCGACATC
GACGGCGAAACATGGCAGCTAGTCGACTTCAACTTCATTCTCCAGCACAACTGA

# Drug_Target_2_General_Function:
Secondary metabolites biosynthesis, transport and catabolism

# Drug_Target_2_General_References:
9495745	Eulberg D, Kourbatova EM, Golovleva LA, Schlomann M: Evolutionary relationship between chlorocatechol catabolic enzymes from Rhodococcus opacus 1CP and their counterparts in proteobacteria: sequence divergence and functional convergence. J Bacteriol. 1998 Mar;180(5):1082-94.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3603

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
28953

# Drug_Target_2_Name:
Chlorocatechol 1,2-dioxygenase

# Drug_Target_2_Number_of_Residues:
257

# Drug_Target_2_PDB_ID:
1S9A

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00775	Dioxygenase_C
PF04444	Dioxygenase_N

# Drug_Target_2_Protein_Sequence:
>Chlorocatechol 1,2-dioxygenase
MANTRVIELFDEFTDLIRDFIVRHEITTPEYETIMQYMISVGEAGEWPLWLDAFFETTVD
SVSYGKGNWTSSAIQGPFFKEGAPLLTGKPATLPMRADEPGDRMRFTGSVRDTSGTPITG
AVIDVWHSTNDGNYSFFSPALPDQYLLRGRVVPAEDGSIEFHSIRPVPYEIPKAGPTGQL
MNSYLGRHSWRPAHIHIRITADGYRPLITQLYFEGDPYLDSDSCSAVKSELVLPVNKIDI
DGETWQLVDFNFILQHN

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
4-chlorocatechol + O(2) = 3-chloro-muconate

# Drug_Target_2_SwissProt_ID:
O67987

# Drug_Target_2_SwissProt_Name:
CLCA_RHOOP

# Drug_Target_2_Synonyms:
EC 1.13.11.-

# Drug_Target_2_Theoretical_pI:
4.53

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasmic

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
J04052

# Drug_Target_3_GenBank_ID_Protein:
150130

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
alpha-LP

# Drug_Target_3_Gene_Sequence:
>1194 bp
ATGTACGTATCGAACCACCGTTCGCGCCGCGTCGCGCGCGTGTCCGTTTCCTGCCTCGTC
GCCGCGCTGGCGGCGATGTCCTGCGGCGCTGCGCTGGCGGCCGATCAGGTCGATCCTCAG
CTGAAATTCGCCATGCAGCGCGATCTGGGCATCTTCCCGACCCAGCTGCCGCAGTACCTG
CAGACCGAAAAACTCGCCCGCACCCAGGCCGCGGCGATCGAGCGCGAGTTCGGTGCCCAG
TTCGCCGGCAGCTGGATCGAGCGCAACGAAGACGGCAGCTTCAAGCTCGTCGCCGCGACC
TCGGGCGCGCGCAAGTCGAGCACGCTGGGCGGGGTGGAAGTGCGCAACGTGCGCTACAGC
CTCAAGCAGCTGCAGTCGGCGATGGAGCAGCTCGACGCCGGCGCCAACGCGCGGGTGAAG
GGCGTCAGCAAGCCGCTCGACGGCGTGCAGAGCTGGTACGTGGATCCGCGCAGCAACGCG
GTGGTGGTCAAAGTCGACGACGGCGCGACGGAAGCCGGCGTCGACTTCGTCGCCCTCAGC
GGCGCCGACAGCGCGCAGGTGCGGATCGAAAGCTCGCCGGGCAAGCTGCAGACCACGGCC
AACATCGTCGGCGGCATCGAGTACTCGATCAACAACGCCTCGCTGTGCTCGGTCGGCTTC
TCGGTCACCCGCGGCGCGACCAAGGGCTTCGTCACCGCCGGCCACTGCGGCACGGTGAAT
GCGACCGCGCGCATCGGCGGCGCGGTGGTCGGCACCTTCGCCGCGCGCGTGTTCCCCGGC
AACGACCGCGCCTGGGTCAGCCTGACCAGCGCGCAGACCCTGCTGCCGCGCGTGGCCAAC
GGCAGCAGCTTCGTCACCGTGCGCGGCAGCACCGAGGCCGCGGTCGGCGCGGCGGTGTGC
CGCTCGGGCCGCACCACCGGTTACCAGTGCGGCACCATCACCGCCAAGAACGTCACCGCC
AACTACGCCGAAGGTGCGGTGCGCGGCCTGACCCAGGGCAACGCCTGTATGGGCCGCGGC
GATTCGGGCGGTTCGTGGATCACCAGCGCCGGCCAGGCGCAGGGCGTGATGTCGGGCGGC
AACGTGCAGTCCAACGGCAACAACTGCGGCATCCCGGCCTCGCAGCGCAGCAGCCTGTTC
GAGCGTCTGCAGCCGATCCTGAGCCAGTACGGCCTGAGCCTGGTCACCGGCTGA

# Drug_Target_3_General_Function:
Involved in serine-type peptidase activity

# Drug_Target_3_General_References:
117110	Brayer GD, Delbaere LT, James MN: Molecular structure of the alpha-lytic protease from Myxobacter 495 at 2.8 Angstroms resolution. J Mol Biol. 1979 Jul 15;131(4):743-75.
3053694	Epstein DM, Wensink PC: The alpha-lytic protease gene of Lysobacter enzymogenes. The nucleotide sequence predicts a large prepro-peptide with homology to pro-peptides of other chymotrypsin-like enzymes. J Biol Chem. 1988 Nov 15;263(32):16586-90.
3234766	Silen JL, McGrath CN, Smith KR, Agard DA: Molecular analysis of the gene encoding alpha-lytic protease: evidence for a preproenzyme. Gene. 1988 Sep 30;69(2):237-44.
3900416	Fujinaga M, Delbaere LT, Brayer GD, James MN: Refined structure of alpha-lytic protease at 1.7 A resolution. Analysis of hydrogen bonding and solvent structure. J Mol Biol. 1985 Aug 5;184(3):479-502.
5482494	Olson MO, Nagabhushan N, Dzwiniel M, Smillie LB, Whitaker DR: Priaary structure of alpha-lytic protease: a bacterial homologue of the pancreatic serine proteases. Nature. 1970 Oct 31;228(5270):438-42.
9724517	Peters RJ, Shiau AK, Sohl JL, Anderson DE, Tang G, Silen JL, Agard DA: Pro region C-terminus:protease active site interactions are critical in catalyzing the folding of alpha-lytic protease. Biochemistry. 1998 Sep 1;37(35):12058-67.
9808037	Sauter NK, Mau T, Rader SD, Agard DA: Structure of alpha-lytic protease complexed with its pro region. Nat Struct Biol. 1998 Nov;5(11):945-50.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
3590

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
41078

# Drug_Target_3_Name:
Alpha-lytic protease

# Drug_Target_3_Number_of_Residues:
397

# Drug_Target_3_PDB_ID:
1SSX

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00089	Trypsin
PF02983	Pro_Al_protease

# Drug_Target_3_Protein_Sequence:
>Alpha-lytic protease precursor
MYVSNHRSRRVARVSVSCLVAALAAMSCGAALAADQVDPQLKFAMQRDLGIFPTQLPQYL
QTEKLARTQAAAIEREFGAQFAGSWIERNEDGSFKLVAATSGARKSSTLGGVEVRNVRYS
LKQLQSAMEQLDAGANARVKGVSKPLDGVQSWYVDPRSNAVVVKVDDGATEAGVDFVALS
GADSAQVRIESSPGKLQTTANIVGGIEYSINNASLCSVGFSVTRGATKGFVTAGHCGTVN
ATARIGGAVVGTFAARVFPGNDRAWVSLTSAQTLLPRVANGSSFVTVRGSTEAAVGAAVC
RSGRTTGYQCGTITAKNVTANYAEGAVRGLTQGNACMGRGDSGGSWITSAGQAQGVMSGG
NVQSNGNNCGIPASQRSSLFERLQPILSQYGLSLVTG

# Drug_Target_3_Reaction:
Preferential cleavage: Ala!, Val! in bacterial cell walls, elastin and other proteins

# Drug_Target_3_Signals:
1-24

# Drug_Target_3_Specific_Function:
Preferential cleavage:Ala-|-Xaa, Val-|-Xaa in bacterial cell walls, elastin and other proteins

# Drug_Target_3_SwissProt_ID:
P00778

# Drug_Target_3_SwissProt_Name:
PRLA_LYSEN

# Drug_Target_3_Synonyms:
Alpha-lytic endopeptidase
Alpha-lytic protease precursor
EC 3.4.21.12

# Drug_Target_3_Theoretical_pI:
9.61

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB04237
